RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mayne Pharma Group Stock

Mayne Pharma Group ROA 2024

Mayne Pharma Group ROA

-0.15

Ticker

MYX.AX

ISIN

AU000000MYX0

WKN

A1C821

In 2024, Mayne Pharma Group's return on assets (ROA) was -0.15, a -30.22% increase from the -0.22 ROA in the previous year.

Mayne Pharma Group Aktienanalyse

What does Mayne Pharma Group do?

Mayne Pharma Group Ltd. is a leading company in the field of pharmaceutical development and production with manufacturing facilities in Australia and the USA. The company is headquartered in Sydney, Australia and employs over 1,100 employees worldwide. The history of Mayne Pharma dates back to 1845 when the company was founded as a manufacturer of herbal medicine. Over the years, the company has evolved and focused on the pharmaceutical industry, eventually being renamed Mayne Nickless Ltd in 1981. In 2000, the company established its subsidiary Mayne Pharma, specializing in the development and production of generic drugs. Through the acquisition of other companies, Mayne Pharma has expanded its product range and expanded into the USA in 2007. Mayne Pharma focuses on the production of generics and specialty pharmaceuticals, which are marketed worldwide through a variety of distribution channels. The company invests heavily in research and development to develop new products and improve existing ones. The goal is to continuously expand the offering and increase market presence. Through the expansion of the product portfolio and the exploration of new markets, Mayne Pharma has gained a strong position in the pharmaceutical industry in recent years. Mayne Pharma is divided into three divisions: generics, specialty pharmaceuticals, and beauty products. The generics division includes a wide range of prescription generic drugs marketed in the USA, Australia, Canada, and other countries. The company is able to produce cost-effective medications to provide affordable drugs to patients worldwide. The specialty pharmaceuticals division focuses on medications for the treatment of diseases such as cancer, pain, and cardiovascular diseases. Mayne Pharma aims to improve treatment outcomes for patients in these areas and has a promising product development pipeline that includes many innovative therapy options. The beauty products division offers a wide range of high-quality skincare products sold worldwide. This includes skin creams, lip care products, and sunscreens. This division is growing steadily and offers great potential, as it operates not only in the healthcare sector but also in the beauty market. Mayne Pharma has a wide range of products, ranging from medications for everyday ailments to life-saving specialty preparations. Key products include: - Doryx: An oral antibiotic therapy for the treatment of mild to moderate acne. - Lonsurf: A cancer-fighting medication that extends the survival time of advanced colorectal cancer patients. - Kapanol: A long-acting opioid for pain relief in patients with severe pain. - Tolsura: An easy-to-use medication for the treatment of fungal infections, particularly suitable for patients who have difficulty swallowing tablets. - Zenavod: A topical medication for the treatment of vaginal infections. - Golden Glow Sunscreen: A high-quality sunscreen with SPF 50+ that prevents skin irritation and sunburn. In conclusion, Mayne Pharma is a proven and innovative company that focuses on the development and production of generics and specialty pharmaceuticals. With its extensive product range and business activities in key international markets, Mayne Pharma has an outstanding reputation in the pharmaceutical industry. Mayne Pharma Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Mayne Pharma Group's Return on Assets (ROA)

Mayne Pharma Group's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Mayne Pharma Group's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Mayne Pharma Group's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Mayne Pharma Group’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Mayne Pharma Group stock

What is the Return on Assets (ROA) of Mayne Pharma Group this year?

The Return on Assets (ROA) of Mayne Pharma Group is -0.15 undefined this year.

What was the ROA of Mayne Pharma Group compared to the previous year?

The ROA of Mayne Pharma Group has increased by -30.22% compared to the previous year.

What consequences do high ROA have for investors of Mayne Pharma Group?

A high ROA is advantageous for investors of Mayne Pharma Group, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Mayne Pharma Group?

A low ROA can be unfavorable for investors of Mayne Pharma Group as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Mayne Pharma Group affect the company?

An increase in ROA of Mayne Pharma Group can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Mayne Pharma Group impact the company?

A reduction in the ROA of Mayne Pharma Group can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Mayne Pharma Group?

Some factors that can influence the ROA of Mayne Pharma Group include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Mayne Pharma Group important for investors?

The ROA of Mayne Pharma Group is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Mayne Pharma Group take to improve ROA?

To improve ROA, Mayne Pharma Group can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Mayne Pharma Group pay?

Over the past 12 months, Mayne Pharma Group paid a dividend of 0.78 AUD . This corresponds to a dividend yield of about 14.5 %. For the coming 12 months, Mayne Pharma Group is expected to pay a dividend of -0.27 AUD.

What is the dividend yield of Mayne Pharma Group?

The current dividend yield of Mayne Pharma Group is 14.5 %.

When does Mayne Pharma Group pay dividends?

Mayne Pharma Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mayne Pharma Group?

Mayne Pharma Group paid dividends every year for the past 1 years.

What is the dividend of Mayne Pharma Group?

For the upcoming 12 months, dividends amounting to -0.27 AUD are expected. This corresponds to a dividend yield of -5.06 %.

In which sector is Mayne Pharma Group located?

Mayne Pharma Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mayne Pharma Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mayne Pharma Group from 1/27/2023 amounting to 0.777 AUD, you needed to have the stock in your portfolio before the ex-date on 1/18/2023.

When did Mayne Pharma Group pay the last dividend?

The last dividend was paid out on 1/27/2023.

What was the dividend of Mayne Pharma Group in the year 2023?

In the year 2023, Mayne Pharma Group distributed 0 AUD as dividends.

In which currency does Mayne Pharma Group pay out the dividend?

The dividends of Mayne Pharma Group are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mayne Pharma Group

Our stock analysis for Mayne Pharma Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mayne Pharma Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.